Since its entry into China, Sumitomo Pharma (Suzhou) Co., Ltd. has worked in three major fields: central nervous system disorders, anti-infection, and cardiovascular diseases. The company has been relieving the suffering of Chinese patients and benefiting them for more than two decades. Further, Sumitomo Pharma (Suzhou) Co., Ltd. understands its responsibility as a pharmaceutical company and hopes to use its expertise to bring a profound impact on the industry's innovation, research, and development.
拉法姆林是Nabriva Therapeutics Ireland DAC公司（总部位于爱尔兰都柏林）研发的截短侧耳素类抗生素，其作用机制不同于现有抗生素，是一种不易产生耐药及交叉耐药的新型抗感染药物。美国食品药品监督管理局（FDA）、加拿大卫生部（Health Canada）及欧洲药品管理局（EMA）已经批准该药用于成人社区获得性细菌性肺炎的治疗，目前在美国以“XENLETA”为商品名销售。拉法姆林也是住友制药在今年5月宣布获得中国大陆以及中国香港、中国台湾等地区独家研发和销售权的4款新产品之一。
According to the Provisions on the Administration of Pharmaceutical Directions and Labels (decree No. 24 of the National Medical Products Administration), after the approval of the revision of drug instructions, drug manufacturers should immediately notify the relevant pharmaceutical trading enterprises, user units, and other departments of the revised content. The company publishes the latest approved specifications as required by the regulations to enable relevant units and medical and health professionals to obtain the latest information timely. The following is only available to health care professionals.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
We use cookies to maintain the proper functioning of our website and to personalize and improve your experience. By clicking “Agree and visit the site” you accept all cookies. For more information, please visit our Privacy Policy.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
